These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 35831099)

  • 1. Administration of brentuximab vedotin to a Hodgkin lymphoma patient with liver dysfunction due to vanishing bile duct syndrome resulting in a partial response without any severe adverse events.
    Ishitsuka K; Yokoyama Y; Baba N; Matsuoka R; Sakamoto N; Sakamoto T; Kusakabe M; Kato T; Kurita N; Nishikii H; Sakata-Yanagimoto M; Obara N; Hasegawa Y; Chiba S
    J Clin Exp Hematop; 2022 Sep; 62(3):154-157. PubMed ID: 35831099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Paraneoplastic Intrahepatic Cholestasis in Supradiaphragmatic Classical Hodgkin Lymphoma Successfully Treated With Brentuximab Vedotin: A Case Report and Review of the Literature.
    Papakonstantinou I; Kosmidou M; Papathanasiou K; Koumpis E; Kapsali E; Milionis H; Vassilakopoulos TP; Papoudou-Bai A; Hatzimichael E
    In Vivo; 2021; 35(4):1951-1957. PubMed ID: 34182468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vanishing bile duct syndrome related to DILI and Hodgkin lymphoma overlap: A rare and severe case.
    Greca RD; Cunha-Silva M; Costa LBE; Costa JGF; Mazo DFC; Sevá-Pereira T; Nascimento MMC; Pereira IE; Oliveira FC; Faria GAS; Neto FLP; Almeida JRS
    Ann Hepatol; 2020; 19(1):107-112. PubMed ID: 31537508
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vanishing bile duct syndrome in a Hodgkin's lymphoma patient with fatal outcome despite lymphoma remission.
    Aleem A; Al-Katari M; Alsaleh K; AlSwat K; Al-Sheikh A
    Saudi J Gastroenterol; 2013; 19(6):286-9. PubMed ID: 24195983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vanishing bile duct syndrome in Hodgkin's lymphoma: A case report and literature review.
    Bakhit M; McCarty TR; Park S; Njei B; Cho M; Karagozian R; Liapakis A
    World J Gastroenterol; 2017 Jan; 23(2):366-372. PubMed ID: 28127210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brentuximab vedotin in combination with sequential procarbazine, cyclophosphamide and prednisolone for the management of Hodgkin's lymphoma-associated vanishing bile duct syndrome (VBDS) with severe obstructive liver failure.
    Fong M; Boyle S; Gutta N
    BMJ Case Rep; 2019 Feb; 12(2):. PubMed ID: 30796069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vanishing Bile Duct Syndrome Secondary to Hodgkin Lymphoma in a Child.
    Palla Velangini S; Boddu D; Balakumar S; Premanand A; Kishore R; Mathew LG
    J Pediatr Hematol Oncol; 2022 Aug; 44(6):e945-e947. PubMed ID: 35796591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vanishing bile duct syndrome as a manifestation of Hodgkin's lymphoma: a case report and review of the literature.
    Nader K; Mok S; Kalra A; Harb A; Schwarting R; Ferber A
    Tumori; 2013; 99(4):e164-8. PubMed ID: 24326854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hodgkin lymphoma-related vanishing bile duct syndrome and idiopathic cholestasis: statistical analysis of all published cases and literature review.
    Ballonoff A; Kavanagh B; Nash R; Drabkin H; Trotter J; Costa L; Rabinovitch R
    Acta Oncol; 2008; 47(5):962-70. PubMed ID: 17906981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vanishing Bile Duct Syndrome in a Patient With Recurrent Hodgkin Lymphoma.
    Nano O; Ivanov S; Kapoor T
    J Med Cases; 2023 May; 14(5):162-168. PubMed ID: 37303969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial.
    Cheson BD; Bartlett NL; LaPlant B; Lee HJ; Advani RJ; Christian B; Diefenbach CS; Feldman TA; Ansell SM
    Lancet Haematol; 2020 Nov; 7(11):e808-e815. PubMed ID: 33010817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vanishing Bile Duct Syndrome in the Presence of Hodgkin Lymphoma.
    Gaudel P; Brown P; Byrd K
    Cureus; 2022 Jul; 14(7):e26842. PubMed ID: 35974868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vanishing bile duct syndrome and immunodeficiency preceding the diagnosis of Hodgkin lymphoma.
    Yeh P; Lokan J; Anantharajah A; Grigg A
    Intern Med J; 2014 Dec; 44(12a):1240-4. PubMed ID: 25442758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1/2 study.
    Lynch RC; Cassaday RD; Smith SD; Fromm JR; Cowan AJ; Warren EH; Shadman MS; Shustov A; Till BG; Ujjani CS; Libby EN; Philip M; Coye H; Martino CN; Bhark SL; Morris K; Rasmussen H; Behnia S; Voutsinas J; Gopal AK
    Lancet Haematol; 2021 Aug; 8(8):e562-e571. PubMed ID: 34329577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brentuximab vedotin with AVD shows safety, in the absence of strong CYP3A4 inhibitors, in newly diagnosed HIV-associated Hodgkin lymphoma.
    Rubinstein PG; Moore PC; Rudek MA; Henry DH; Ramos JC; Ratner L; Reid E; Sharon E; Noy A;
    AIDS; 2018 Mar; 32(5):605-611. PubMed ID: 29280762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinicopathologic features of drug-induced vanishing bile duct syndrome].
    Ye LH; Wang CK; Zhang HC; Liu ZQ; Zheng HW
    Zhonghua Gan Zang Bing Za Zhi; 2017 Apr; 25(4):317-320. PubMed ID: 28494557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A targeted salvage therapy with Brentuximab vedotin in heavily treated refractory or relapsed pediatric Hodgkin lymphoma patients before and after stem cell transplantation.
    Taçyıldız N; Tanyıldız HG; Ünal E; Dinçaslan H; Asarcıklı F; Aksoy BA; Vatansever G; Yavuz G
    Turk J Pediatr; 2019; 61(5):671-676. PubMed ID: 32104998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pulmonary toxicity in paediatric patients with relapsed or refractory Hodgkin lymphoma receiving brentuximab vedotin.
    Faulk KE; Sopfe JM; Campbell K; Liptzin DR; Liu AK; Franklin ARK; Cost CR
    Br J Haematol; 2018 Oct; 183(2):251-256. PubMed ID: 30198571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial.
    Diefenbach CS; Hong F; Ambinder RF; Cohen JB; Robertson MJ; David KA; Advani RH; Fenske TS; Barta SK; Palmisiano ND; Svoboda J; Morgan DS; Karmali R; Sharon E; Streicher H; Kahl BS; Ansell SM
    Lancet Haematol; 2020 Sep; 7(9):e660-e670. PubMed ID: 32853585
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study.
    Kuruvilla J; Ramchandren R; Santoro A; Paszkiewicz-Kozik E; Gasiorowski R; Johnson NA; Fogliatto LM; Goncalves I; de Oliveira JSR; Buccheri V; Perini GF; Goldschmidt N; Kriachok I; Dickinson M; Komarnicki M; McDonald A; Ozcan M; Sekiguchi N; Zhu Y; Nahar A; Marinello P; Zinzani PL;
    Lancet Oncol; 2021 Apr; 22(4):512-524. PubMed ID: 33721562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.